Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
1045 Sansome St, Suite 321, San Francisco, CA
hello@withpower.com(415) 900-4227
About UsClinical Trials by ConditionAll Clinical TrialsWork With Us
1
Directories
Conditions
Cities
States
Popular Categories
Depression & Anxiety
Neurology
Psychiatry
Pain
Metabolism
Treatments
Locations
Florida
New Jersey
North Carolina
Texas
Ohio
California
Pennsylvania
Kentucky
New York
Indiana
Psychology Related
Depression
Schizophrenia
Anxiety
PTSD
ADHD
Autism
Bipolar Disorder
Addiction
OCD
Eating Disorder
Treatments
Psilocybin
IVF
Dental Implant
Weight Loss
Smoking
Platelet-Rich Plasma
Testosterone
Saxenda
Melatonin
Entresto
Cities
Saint Louis
Columbus
Portland
Ann Arbor
Aurora
Salt Lake City
Rochester
Birmingham
Detroit
New Haven
Terms of Service·Privacy Policy·Cookies
Cookies & Data Use Policy

At Power, we believe in using data responsibly to help you find the right clinical trials — without compromising your privacy. This page explains how we use cookies and personal data across www.withpower.com.

Before You Create a Profile

When you browse Power's website, you're opting in to our use of cookies. Cookies are used to improve your experience and help us understand how the site is used so that we can make improvements for you in the future. Specifically, we use cookies to:

Personalize Your Experience

We use cookies to customize your visit based on basic information like your general location (determined by your IP address). This allows us to:

  • Show you clinical trials that are geographically relevant to you
  • Tailor search results to match the conditions or keywords you've explored before
  • Pre-fill certain fields or remember your previous searches, so you don't have to repeat them

Save Your Preferences

We remember what you interact with during your visit — for example:

  • The conditions you search for
  • Whether you prefer certain types of studies (e.g., paid trials, trials for a specific age group)
  • Your sorting or filtering preferences when browsing trials

This helps us make your experience more efficient and personalized the next time you visit.

Understand How the Site Is Used

Cookies help us collect anonymous usage data so we can make Power better. We use these insights to:

  • Monitor how users move through the site — for example, which pages get the most traffic and where users tend to exit
  • Track how long visitors stay on each page and whether they find what they’re looking for
  • Identify points of friction or confusion so we can improve usability
  • Test design changes (like different page layouts or buttons) and measure which version performs better
  • Detect and fix bugs or slow-loading pages to maintain site reliability

These analytics are aggregated and do not include personal identifiers. We use tools like Google Analytics to process this data, but we don't use it to target ads or sell your information.

We do not:

  • Sell or share your personal data with advertisers
  • Use your behavior on our site to target you with third-party ads

All cookie use is designed to support your experience on Power — never to track you across the internet or monetize your information.

After You Create a Profile

When you sign up for a Power account, you agree to our Privacy Policy and Terms of Service. Creating a profile allows us to better serve you by tailoring the platform to your specific needs.

Once you create a profile:

  • We may collect additional information about your health and clinical interests to help us match you to the most relevant studies.
  • We continue to use cookies to remember your session, keep you logged in, and personalize your dashboard.
  • You have full control — you can delete your profile at any time, and we'll remove your personal data in accordance with our privacy practices.

We use your data solely to fulfill our mission: helping you find clinical trials that could be a fit — not for advertising or resale.

·Security
Condition
Suggested Conditions
  • Anxiety
  • Depression
  • Alzheimer's Disease
  • Weight Loss
  • Heart Disease
  • Cancer
  • Asthma
Location

    Autism

    Current Location

    Search
    Autism
    Show Map
    Map View
    Your Location

    Popular Searches

    By Condition

    Depression Clinical Trials

    Anxiety Clinical Trials

    Schizophrenia Clinical Trials

    ADHD Clinical Trials

    Bipolar Disorder Clinical Trials

    Multiple Sclerosis Clinical Trials

    Autism Clinical Trials

    Treatment Resistant Depression Clinical Trials

    Borderline Personality Disorder Clinical Trials

    Social Anxiety Disorder Clinical Trials

    Parkinson's Disease Clinical Trials

    Alzheimer's Disease Clinical Trials

    By Location

    Clinical Trials in California

    Clinical Trials in Florida

    Clinical Trials in Texas

    Clinical Trials in New York

    Clinical Trials in Ohio

    Clinical Trials in Illinois

    Clinical Trials in Pennsylvania

    Clinical Trials in Michigan

    Clinical Trials in North Carolina

    Clinical Trials in Massachusetts

    Clinical Trials in Missouri

    Clinical Trials in Minnesota

    Other People Viewed

    By Subject

    13 Autism Trials near Dallas, TX

    15 Autism Trials near Chicago, IL

    Top Autism Clinical Trials near Miami, FL

    Top Autism Clinical Trials near San Diego, CA

    Top Autism Clinical Trials near Long Beach, CA

    4 Autism Trials near Tampa, FL

    30 Autism Trials near Albuquerque, NM

    14 Autism Trials near Cincinnati, OH

    Top Fibroids Clinical Trials

    Top Sarcoidosis Clinical Trials

    Top Epilepsy Clinical Trials

    Top Hypoglycemia Clinical Trials

    By Trial

    Levoleucovorin Calcium for Autism

    Sulforaphane for Autism

    Specialized Employment Program for Autism

    Pregnenolone for Autism

    Sertraline + Cognitive Behavioural Therapy for Anxiety in Autism

    Bedtime Routine for Autism

    Propofol-Etomidate Admixtures for Anesthesia

    ASP4396 for Solid Tumors

    Mobile Health and Social Media Intervention for Cancer Survivors

    Driver Training for Reducing Car Accidents

    Whole Brain vs Stereotactic Radiation for Brain Cancer

    Selective Dorsal Rhizotomy for Cerebral Palsy

    Related Searches

    Top Diabetes-type-2 Clinical Trials

    Top Treatment for Ibrutinib Clinical Trials

    Top Treatment for Carfilzomib Clinical Trials

    Top Treatment for Apixaban Clinical Trials

    Top Nafld Clinical Trials

    Provider Training and Patient Education for HIV Prevention

    AGTC-501 for Retinitis Pigmentosa

    Stem Cell Addback for Leukemia

    Cupping for Stroke Rehabilitation

    Adoptive T Cell Therapy for Adenovirus Infections After Bone Marrow Transplant

    Top Clinical Trials near Dallas, TX

    Enema Flush Regimen for Constipation

    Search Clinical Trials
    Conditions
    Suggestions
    • Anxiety
    • Depression
    • Alzheimer's Disease
    • Weight Loss
    • Heart Disease
    • Cancer
    • Asthma
    Locations
    Suggestions
      Treatment Type
      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Trial Phase

      Trial Status

      Paid Participation

      Filters

      0

      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Paid Participation

      Trial Status

      Trial Phase

      Clear All
      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

      121 Autism Trials Near You

      Power is an online platform that helps thousands of Autism patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

      Learn More About Power
      No Placebo
      Highly Paid
      Stay on Current Meds
      Pivotal Trials (Near Approval)
      Breakthrough Medication

      Simplified Language for Autism

      East Lansing, Michigan
      The long-term study goal is to experimentally evaluate the components (and likely active ingredients) of early language interventions for young children with ASD. The overall objective is to determine how single-word and telegraphic simplification affects real-time language processing and word learning in young children with ASD (relative to full, grammatical utterances). The proposed project will investigate three specific aims: 1) Determine how single-word and telegraphic simplification affects language processing. 2) Determine how single-word and telegraphic simplification affects word learning. 3) Evaluate child characteristics that may moderate the effects of linguistic simplification on language processing and word learning. Aim 1 will test the hypothesis that children with ASD will process full, grammatical utterances faster and more accurately than single-word or telegraphic utterances. Aim 2 will test the hypothesis that full, grammatical utterances will support word learning better than telegraphic or single-word utterances. Aim 3 will test the hypothesis that language and cognitive skills significantly moderate the effects of linguistic simplification on language processing and word learning in young children with ASD.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:1 - 4

      Key Eligibility Criteria

      Disqualifiers:Genetic Conditions, Cerebral Palsy, Brain Injury, Others

      104 Participants Needed

      Reciprocal Imitation Training for Autism

      East Lansing, Michigan
      This study is evaluating whether a parent-mediated intervention can improve outcomes for children with autism.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:16 - 33

      Key Eligibility Criteria

      Disqualifiers:Visual, Hearing, Motor Conditions

      440 Participants Needed

      Interactive Virtual Workday Training for Autism

      Plainwell, Michigan
      Nearly 50,000 youth with autism spectrum disorder (ASD) transition from high school to adult life each year with only 25% of these transition-age youth with ASD (TAY-ASD) getting jobs within 2 years of graduation. TAY-ASD's ability to sustain employment is even more challenging due in part to their social cognitive deficits (e.g., poorly reading social cues) that disrupt communicating with customers, coworkers, and supervisors. Research shows nearly 90% of job dismissals among TAY-ASD are attributed to poor work-based social functioning (e.g., poorly communicating with upset customers). The subsequent unemployment has damaging effects on their mental, physical, and economic health. A critical gap in federally-mandated services to support youth with ASD as they transition from school-to-adult life is the lack of evidence-based practice to enhance work-based social functioning. Given that TAY-ASD report computerized training tools (developed by the investigators and others) are highly acceptable and improve their real-world outcomes, the investigators propose to address this critical barrier to sustained employment by developing and evaluating a novel and scalable computerized training tool to enhance participant conversations with customers, coworkers and supervisors at work. The investigators propose to develop and test the effectiveness of Social Cognitive and Affective Learning for Work (Work Chat: An Interactive Virtual Workday), a computerized training tool. Work Chat will have three tiers of instruction designed to help TAY-ASD prepare for effective workplace communication. Tier 1 will adapt existing evidence-based practices to design an e-learning curriculum that trains social cognitive strategies to help guide work-related conversations (e.g., reading social cues or regulating emotions during supervisor feedback). In Tier 2, SIMmersion's PeopleSim® technology will enable TAY-ASD to apply social cognitive strategies learned in Tier 1 to repetitively practice simulated conversations with a fictional customer, coworker, or supervisor. In Tier 3, SIMmersion will innovate PeopleSim to exist in an interactive 3-D environment to create a virtual workday with interconnected activities were the actions made early in the day influence conversations later in the day (e.g., a poor customer interaction may result in constructive feedback from a supervisor). Phase I (Feasibility) was completed with application HUM00177878. Phase II (Efficacy) Aims: Aim 1) Complete Work Chat development using an iterative process that includes initial and ongoing individual-level feedback from Phase I participants and the community and scientific advisory boards to complete the product that will be evaluated in Aims 2-3. Aim 2) Conduct a Randomized Controlled Effectiveness-Implementation hybrid trial in a school setting to evaluate Work Chat. The investigators will recruit and randomly assign n=338 TAY-ASD (90% of sample frame) enrolled in school-based standard transition services (STS) to the Work Chat group (STS+SW) or a STS group (STS). The hypothesis is that STS+SW, compared to STS, will show greater gains in: (H1) social cognition and (H2) work-based social functioning; as well as (H3) reduced anxiety about work-based social encounters, and (H4) greater sustained employment by 9-month follow-up. The investigators will test mechanistic hypotheses (H5a-b) that social cognitive ability (H5a) and work-based social functioning (H5b) mediate the effect of treatment (STS+SW vs. STS) on sustained employment. For the implementation evaluation, the investigators will conduct a multilevel, mixed-method process evaluation of Work Chat's acceptability, appropriateness, and feasibility. Aim 3) Use community participatory research methods to prepare for commercialization. The investigators will conduct a parallel multilevel, mixed method implementation evaluation that focuses on the Work Chat delivery system regarding its feasibility, sustainability, scalability, and generalizability by conduct focus groups with delivery staff and administrators. These groups will discuss potential facilitators and barriers to Work Chat implementation, adoption, and sustainability.
      No Placebo Group

      Trial Details

      Trial Status:Enrolling By Invitation
      Trial Phase:Unphased
      Age:16+

      Key Eligibility Criteria

      Disqualifiers:Traumatic Brain Injury, Vision, Hearing, Others

      300 Participants Needed

      Caregiver Training for Autism Spectrum Disorder

      London, Ontario
      "More Than Words® - The Hanen Program® for Parents of Autistic Children or Children Who May Benefit from Social Communication Support" is a family-focused intervention program delivered by a speech-language pathologist (SLP). The goal of More Than Words is to empower parents to be the main facilitator of their child's social communication development, which increases the child's opportunities to develop social communication skills in everyday situations. It is one of the programs offered to families who receive services from Ontario's Preschool Speech and Language program, although some regions are not able to offer it at all or are only able to offer a shortened version of the program. The Hanen Centre recently made updates to the More Than Words program to allow it to be delivered virtually (online) and to align with the latest evidence. Past research has found some evidence that the More Than Words program is effective, but knowledge is needed about the latest version of the program, including how effective it is when delivered online. It is important to understand who this program works best for and why. The purpose of the current study, called a pilot study, is to test a study plan that could be used in a future large study to answer these questions. In this pilot study, the investigators will test procedures for comparing the outcomes of families who receive the More Than Words program to families who have not yet received it. Additionally, procedures for understanding varying responses to treatment will be tested. The study aims to determine whether the methods used for recruiting families, delivering the program, and monitoring progress are practical and function as expected in preparation for the future large-scale study.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:< 47

      Key Eligibility Criteria

      Disqualifiers:Over 48 Months, No Internet, Others

      72 Participants Needed

      Sertraline for Anxiety in Neurodevelopmental Disorders

      London, Ontario
      There are currently no approved medications for the treatment of anxiety in children and youth with neurodevelopmental disorders (NDDs), both common and rare. Sertraline, a selective serotonin reuptake inhibitor, has extensive evidence to support its use in children's and youth with anxiety but not within NDDs. More research is needed to confirm whether or not sertraline could help improve anxiety in children and youth with common and rare neurodevelopmental conditions. This is a pilot study, in which we plan to estimate the effect size of reduction in anxiety of sertraline vs. placebo. across rare and common neurodevelopmental disorders, and determine the best measure(s) to be used as a primary transdiagnostic outcome measure of anxiety, as well as diagnosis specific measures in future, larger-scale clinical trials of anxiety in NDDs.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Age:8 - 17

      Key Eligibility Criteria

      Disqualifiers:Diabetes, HIV, Hepatitis, Others
      Must Not Be Taking:SSRIs, MAOIs, Pimozide, Others

      130 Participants Needed

      Cognitive Behavioral Therapy for Anxiety in Children with Autism and Intellectual Disability

      London, Ontario
      Anxiety can be a debilitating and common concomitant diagnosis in autism spectrum disorders (ASD). Dependent on age and subtype of anxiety, the prevalence of anxiety in individuals with autism ranges between 1.7-84%. Meanwhile, the prevalence rate of intellectual disability (ID) in individuals with ASD ranges between 50-80% based on previous studies. There is an even greater risk of anxiety, ranging between 13.6- 43%, in individuals with ASD and ID. Despite the high prevalence of anxiety within this population, there are limited studies exploring assessments and treatments geared towards addressing anxiety in autism and intellectual disabilities. Previous studies have been limited to children who are identified as high functioning, or identified as low functioning without a concomitant diagnosis of ID. Given this, the present study focuses on the population of individuals with ASD and ID by exploring the feasibility of a CBT intervention designed for individuals with high-functioning autism This pilot study aims at addressing and treating anxiety in children with ASD and intellectual disability through the Facing Your Fears (FYF) intervention. Facing Your Fears is a cognitive behavioral therapy (CBT) program specifically designed to address anxiety symptoms in children with autism. Research exploring the effectiveness of the FYF intervention within the population of individuals with ASD and ID is limited. This study aims at evaluating the feasibility of the Facing Your Fears program to address anxiety in children with ASD and ID, while evaluating the effectiveness of this intervention in larger group settings. The duration of the study will run over two 12-week cycles with study assessments conducted in-person, once a week. The study will involve 5-6 parent-child dyads to make up 10-12 participants per cycle. The child participants must be between the ages of 12-18 years old and have a confirmed diagnosis of ASD that meets DSM-V criteria. The study will commence with a month of recruitment, and a month allotted for collating data and assessments, before and after each 12-week intervention cycle. Evaluations will take place at screening, every study visit, and post intervention. Alongside the study evaluations, weekly sessions will involve didactic and practice sessions, with the last 30 minutes reserved for parent training. The sessions focus on the use and generalization of the taught strategies to address anxious symptoms, and exposure sessions outside of the weekly sessions. At the end of the 12-week cycle, the assessments related to the study outcomes will be administered again to allow investigators to compare and analyze pre- and post-intervention scores.
      No Placebo Group

      Trial Details

      Trial Status:Not Yet Recruiting
      Trial Phase:Unphased
      Age:12 - 18

      Key Eligibility Criteria

      Disqualifiers:Suicidal Ideations, Concurrent Study, Others

      24 Participants Needed

      CBT vs Mindfulness-Based Therapy for Autism

      Charlottesville, Virginia
      Autistic adults are at a greater risk for mental health problems compared to the general population, with 50% meeting criteria for a co-occurring psychiatric condition. Depression and anxiety are the most common of these conditions among autistic adults, contributing to long-term detrimental effects on health, day-to-day functioning, and quality of life. This study will conduct the first large-scale head-to-head comparison of the two most widely studied mental health interventions for autistic adults: cognitive-behavioral therapy (CBT) and mindfulness-based therapy (MBT). Both interventions are well-established, empirically supported treatments for depression and anxiety in the general population, and both interventions have demonstrated efficacy among autistic adults. However, their comparative effectiveness and heterogeneity of treatment effects have not been established in autistic adults. Both interventions will be delivered by telehealth.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Acute Psychosis, Intoxication, Mania, Others

      300 Participants Needed

      Motor Synchrony Games for Autism Spectrum Disorder

      Boone, North Carolina
      The goal of this study is to determine if progressively more challenging playground games (motor synchrony games) improve executive function in preschool-aged children.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Age:2 - 5

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      24 Participants Needed

      Family Service Navigation for Autism

      Champaign, Illinois
      The purpose of this study is to develop and test a family navigator training and an app (a technology-based treatment support system) for low-resourced families of young children (aged 3-5) with autism. The hypothesis is that the navigator training and treatment support system will help enable navigators to support families of young children with autism in accessing needed services.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Not Meeting Inclusion Criteria

      55 Participants Needed

      Family Check-Up for Autism

      Hamilton, Ontario
      Many children and youth with autism spectrum disorder have high levels of emotional and behavioural problems. Parents play a powerful role in supporting their children's well-being. Research also shows that certain factors (e.g., parent mental health, access to services) can affect autistic children's well-being in important ways. Despite this, autism services rarely ask about, or act upon, the factors that we know affect child and family well-being. We are addressing this problem by testing a program called the Family Check-Up within a large autism service. The Family Check-Up is a strengths-based, family-centred program aimed at improving child well-being by working with parents to identify their family's unique strengths and challenges, set goals for change, strengthen positive parenting, and connect to needed supports.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Age:6 - 17

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      80 Participants Needed

      Oxytocin Nasal Spray for Autism

      Charlottesville, Virginia
      This trial tests if giving oxytocin through a nasal spray can improve bone health in children with autism. Children with autism often have weaker bones and lower levels of oxytocin. The study aims to see if oxytocin can help make their bones stronger. Oxytocin has been investigated for its potential to treat social deficits in autism spectrum disorders, with various studies exploring its effects on social behavior and brain function.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Age:6 - 18

      Key Eligibility Criteria

      Disqualifiers:Fragile X, Tuberous Sclerosis, Others
      Must Not Be Taking:Bone Medications

      96 Participants Needed

      Caregiver Interventions for Autism

      Charlottesville, Virginia
      Autism spectrum disorder affects 1-2% of children worldwide, yet access to quality care remains limited, especially in underserved communities. Families face systemic barriers such as workforce shortages, high caregiver stress, and a lack of culturally appropriate services. To address these gaps, researchers developed a group-based caregiver training program to improve caregiver well-being and child communication and behavior. Successfully piloted in rural U.S. communities and western Kenya through the AMPATH Program, the intervention showed promising results in reducing caregiver stress and autism severity. Building on this success, a new study will evaluate two delivery models-professionally-led and peer-led-using a rigorous effectiveness-implementation trial. The project applies a reciprocal innovation approach, using insights from Kenya to inform U.S. strategies for scaling community-based autism support. The long-term goal is to reduce disparities in autism care by creating scalable, low-cost, caregiver-driven models. A Community Advisory Panel will guide the research to ensure relevance and impact. This initiative represents a transformative step toward equitable autism services across global and U.S. settings.
      No Placebo Group

      Trial Details

      Trial Status:Not Yet Recruiting
      Trial Phase:Unphased
      Age:2 - 8

      Key Eligibility Criteria

      Disqualifiers:Vision, Hearing Impairment, Others

      320 Participants Needed

      Parental Interventions for Young Children with Autism

      Evanston, Illinois
      The overarching goal of the proposed study is to: (a) determine how best to sequence two parent-mediated interventions: a social communication intervention (Project ImPACT, Improving Parents as Communication Teachers) and a disruptive behavior intervention (Parent Training for Disruptive Behavior) and (b) examine moderators and mediators of intervention outcomes.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Age:18 - 48

      Key Eligibility Criteria

      Disqualifiers:Other Diagnosis, Disability, Vision Impairment, Others

      184 Participants Needed

      Virtual Reality for Autism

      Westchester, Illinois
      The goal of this randomized clinical trial is to compare and learn about Virtual Reality (VR) in children with autism/Autistic children. The main question it aims to answer is: • Does the Floreo VR clinical product show clinical improvement in autism symptoms? Participants will engage the VR product for twice a week for twelve weeks. They will be randomized to either the Floreo Clinical Product or a VR Control group experience. Researchers will compare the two groups to see if there is an effect on learning specific skills and behaviors.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased
      Age:5 - 18

      Key Eligibility Criteria

      Disqualifiers:Epilepsy, Migraine, Vertigo, Others

      100 Participants Needed

      After-School Social Intervention for Autism

      Buffalo, New York
      Social skills interventions are sometimes used to treat the social impairments of higher-functioning children with autism spectrum disorder (hfASD; without intellectual disability). Despite the recognized need for such treatments, few children with hfASD receive social interventions. Efforts to develop and implement school social interventions have been hindered by barriers during the school day (e.g., lack of resources, staffing, training, and time). As such, there is a need for feasible and effective social interventions that can be delivered by non-professional (paraprofessional) school staff in school settings including after-school programs. The purpose of this study is to test the feasibility and initial efficacy of an after-school social intervention delivered by paraprofessionals in school settings for children with hfASD. Children will be randomly assigned to the social intervention group or a no-treatment control (waitlist) group. The intervention will be delivered by paraprofessionals four days per week (90 minutes per session) over eight weeks during the children's after-school program conducted at their schools. Sessions include social skills groups, social recreational games to practice skills, and behavioral reinforcement to strengthen learning. Feasibility will be assessed via implementation fidelity (accuracy), parent and child satisfaction ratings, and attendance and attrition rates. Outcomes will test the intervention effect on a child test of social-cognition, parent ratings of social skills and ASD symptoms, and behavioral coding of social competence by naïve raters during unstructured game play. Child outcome measures will be completed for both the social intervention group and no-treatment control (waitlist) group immediately prior to (pretest) and following (posttest) the eight-week intervention, and children initially assigned to the social intervention will also complete the assessments three months later (follow-up). Children assigned to the no-treatment control (waitlist) group will receive the social intervention after the intervention group completes the social intervention.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:7 - 12

      Key Eligibility Criteria

      Disqualifiers:Psychosis

      48 Participants Needed

      Executive Function Treatment for Autism Spectrum Disorder

      Rockville, Maryland
      This trial tests a school-based program called UOT:HS for high school students with autism. The program aims to improve planning and flexibility skills through lessons and parental involvement to help students succeed after high school.
      No Placebo Group

      Trial Details

      Trial Status:Enrolling By Invitation
      Trial Phase:Unphased
      Age:14 - 22

      Key Eligibility Criteria

      Disqualifiers:Non-English Proficiency, Others

      224 Participants Needed

      rTMS for Depression in Autism

      Toronto, Ontario
      The current clinical trial is focused on evaluating the efficacy of rTMS for treatment of depression in youth and young adults (hereafter called transition aged youth, TAY) with autism spectrum disorder (ASD). The motivation to undertake the current efficacy study is driven by: (1) the substantial impact of depression on TAY with ASD (based on prevalence and contribution to disability/impairment); (2) lack of evidence-based treatments for depression in autism (there are no current trials rigorously evaluating any treatment for depression, i.e., psychotherapeutic, pharmacotherapeutic, brain stimulation); (3) rTMS has demonstrated efficacy in non-autistic individuals to improve symptoms of depression and may be better tolerated in youth than medication treatment; (4) a prior pilot rTMS study focused on treatment of executive function deficits in autism indicated that high frequency rTMS delivered using a rigorous randomized control trial (RCT) protocol can be feasibly implemented in TAY with autism, is well tolerated (mild to moderate adverse effects and low drop out), and has the potential to improve symptoms of depression.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:16 - 35

      Key Eligibility Criteria

      Disqualifiers:Substance Use Disorder, Seizures, Pregnancy, Others
      Must Not Be Taking:Benzodiazepines, Anticonvulsants

      80 Participants Needed

      rTMS for Autism

      Toronto, Ontario
      In the current project, investigators have two main goals: i) Testing whether an excessive plasticity, i.e. hyperplasticity in the motor cortex underlies motor function difficulties in autistic adults, and ii) Using repetitive Transcranial Magnetic Stimulation (rTMS) with autistic adults to examine whether resulting reduced hyperplasticity in the motor cortex will be associated with clinical improvements in the motor function.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:18 - 40

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Substance Use Disorder, Others
      Must Not Be Taking:Benzodiazepines, Anticonvulsants

      150 Participants Needed

      Virtual Group Social ABCs for Autism

      Toronto, Ontario
      The goal of this randomized control trial is to test the efficacy of the Social ABCs 6 week, group-based model using a virtual delivery platform. The Social ABCs is a caregiver-mediated early intervention program, aiming to increase child skills in directed, intentional vocalizations, and shared smiling with a primary caregiver for toddlers identified as early signs or a confirmed diagnosis of autism spectrum disorder (ASD), or having related social communication challenges. A positive RCT was previously completed using the program's in-person individual, 12-week model, and a pilot study showing preliminary promise of the virtual group-based model has also been published. This adaptation to a virtual, group-based model maintains the core components of the intervention, but allows caregivers to meet and discuss the content as a group from their home environments and complete the program in a shorter timeframe. The main questions it aims to answer are: * Is the Social ABCs virtual group-based model an effective early intervention program for toddlers aged 12-42 months with probable or confirmed ASD, or experiencing social communication challenges, when compared to an active control condition? * Can primary caregivers of these toddlers achieve implementation fidelity in the Social ABCs intervention strategies using the 6-week virtual delivery model? Participants will be randomized into the treatment condition (A) where they will receive the Social ABCs virtual group-based intervention or, into a Control condition (B), where they meet virtually with other caregivers in the control groups over the course of 6 weeks, viewing and discussing 3 didactic presentations around general child development content (not autism- or Social ABCs-specific). Video and questionnaire data will be collected before (Time 0) and after (Time 1) the 6 week period. After an additional 6-8 weeks, the same data will be collected from both groups as a follow-up time point (Time 2). Researchers will compare the Treatment group and the Control group to measure change in the target behaviours for the child, the caregiver's use of strategies, as well as caregiver stress and self-efficacy, across time-points.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased
      Age:12 - 42

      Key Eligibility Criteria

      Disqualifiers:Neurological, Genetic, Severe Sensory, Others

      120 Participants Needed

      rTMS for Autism

      Toronto, Ontario
      This trial will test if using magnetic fields to stimulate the brain can help children and youth with autism manage their emotions better and reduce disruptive behaviors. The study will observe the effects over a short period to see if it works.

      Trial Details

      Trial Status:Recruiting
      Age:9 - 18

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      50 Participants Needed

      Why Other Patients Applied

      "I have dealt with voice and vocal fold issues related to paralysis for over 12 years. This problem has negatively impacted virtually every facet of my life. I am an otherwise healthy 48 year old married father of 3 living. My youngest daughter is 12 and has never heard my real voice. I am now having breathing issues related to the paralysis as well as trouble swallowing some liquids. In my research I have seen some recent trials focused on helping people like me."

      AG
      Paralysis PatientAge: 50

      "I've been struggling with ADHD and anxiety since I was 9 years old. I'm currently 30. I really don't like how numb the medications make me feel. And especially now, that I've lost my grandma and my aunt 8 days apart, my anxiety has been even worse. So I'm trying to find something new."

      FF
      ADHD PatientAge: 31

      "I was diagnosed with stage 4 pancreatic cancer three months ago, metastatic to my liver, and I have been receiving and responding well to chemotherapy. My blood work revealed that my tumor markers have gone from 2600 in the beginning to 173 as of now, even with the delay in treatment, they are not going up. CT Scans reveal they have been shrinking as well. However, chemo is seriously deteriorating my body. I have 4 more treatments to go in this 12 treatment cycle. I am just interested in learning about my other options, if any are available to me."

      ID
      Pancreatic Cancer PatientAge: 40

      "As a healthy volunteer, I like to participate in as many trials as I'm able to. It's a good way to help research and earn money."

      IZ
      Healthy Volunteer PatientAge: 38

      "I changed my diet in 2020 and I’ve lost 95 pounds from my highest weight (283). I am 5’3”, female, and now 188. I still have a 33 BMI. I've been doing research on alternative approaches to continue my progress, which brought me here to consider clinical trials."

      WR
      Obesity PatientAge: 58
      Match to a Autism Trial

      At-home tDCS for Autism

      Toronto, Ontario
      Transcranial direct current stimulation (tDCS) is a form of non-invasive brain stimulation that can be delivered in a home setting. It is a safe and tolerable intervention that has shown promise for improving positive social communication and self-regulation in youth with Autism Spectrum Disorder (ASD). Children and youth with ASD will be randomized to At-home tDCS or sham control stimulation for 3 weeks. We will measure the effect of At-home tDCS on the brain mechanisms and clinical measures of social communication and self-regulation..

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Age:9 - 18

      Key Eligibility Criteria

      Disqualifiers:Seizures, Metal Implants, Epilepsy, Others

      20 Participants Needed

      Psilocybin for Depression in Autism

      Toronto, Ontario
      We propose a first-of-its-kind open-label clinical trial to investigate the feasibility, tolerability, and safety of administering psilocybin in autistic adults with treatment-resistant depression (TRD). In this study, 20 participants (intellectually able and fluent-speech adults) with autism and co-occurring TRD will receive around 20 hours of manualized psychotherapy that has previously been used with psilocybin (Agin-Liebes et al., 2020). They will also receive psilocybin at 2 different time points, firstly a safety dose of 10mg, followed by a treatment dose of 25mg. This study design is in accordance with previous studies investigating the use of psilocybin with psilocybin-assisted therapy (PAT) to treat TRD (Carhart-Harris et al., 2016, 2018)
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1
      Age:18 - 65

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Seizure Disorder, Substance Use, Others
      Must Not Be Taking:Antidepressants, Antipsychotics, Ketamine, Others

      20 Participants Needed

      Deep Brain Stimulation for Self-Harm in Children with Autism

      Toronto, Ontario
      Deep Brain Stimulation for the Treatment of Severe Refractory Self-Injurious Behaviour in Children with Autism Spectrum Disorder: A Randomized Trial To evaluate the effectiveness of deep brain stimulation (DBS) of the nucleus accumbens for the treatment of severe refractory, repetitive self-injurious behavior (SIB) in children with Autism Spectrum Disorder. Secondary objectives are to examine the effects of DBS on subtypes of SIB through functional analysis.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:5 - 17

      Key Eligibility Criteria

      Disqualifiers:Substance Abuse, Cardiac Arrhythmias, Others

      25 Participants Needed

      Transcranial Direct Current Stimulation for Autism

      Washington D.C., District of Columbia
      This trial is testing whether brain stimulation can improve social and thinking skills in young adults with autism. The treatment involves using electrical or magnetic stimulation on specific parts of the brain. Researchers hope this will help people with autism communicate better and think more flexibly. The new method aims to enhance cognitive, motor, and social communication abilities.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:18 - 35

      Key Eligibility Criteria

      Disqualifiers:Neurological Condition, Brain Injury, Others
      Must Not Be Taking:Psychotropic Medication

      80 Participants Needed

      Executive Function Group Therapy for Autism Spectrum Disorder

      Washington, District of Columbia
      This project explores the association between learning and cognitive flexibility by testing whether a cognitive behavioral intervention designed to improve flexibility in ASD changes learning and associated neural activation using model-based functional magnetic resonance imaging (m-fMRI). The study proposes that variability in learning mechanisms is associated with behavioral flexibility and explains differences in adaptive and treatment outcomes. The study employs a longitudinal case-controlled design in 60 14-18 year old youth with ASD at 3 time-points 8 months apart, each including m-fMRI during learning and behavioral measurement of executive and adaptive function. Aim 1 tests the hypothesis that individual variation in learning biases and their neural correlates predicts behavioral flexibility and is stable over time. Aim 2 tests plasticity of learning mechanisms induced by a cognitive-behavioral intervention for flexibility. Aim 3 tests hypothesis about intervention-induced plasticity of neural functional connectivity.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased
      Age:14 - 18

      Key Eligibility Criteria

      Disqualifiers:Neurological Disorder, Metal Implants, Pregnancy, Others

      64 Participants Needed

      Milieu Teaching-AV for Autism

      Nashville, Tennessee
      This project will look at whether a novel approach to language intervention that encourages looking to audiovisual speech cues for infants with autistic older siblings (Baby Sibs), who are highly likely be diagnosed with autism or developmental language disorder (DLD). This study will specifically look at (a) whether caregivers find this approach to be easy to implement in their homes, (b) whether they find this approach to be acceptable, and (c) whether caregivers use the taught strategies in interactions with their infants.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:5 - 12

      Key Eligibility Criteria

      Disqualifiers:Neurological History, Genetic Condition, Pre-term Birth, Vision Impairment, Hearing Loss

      8 Participants Needed

      Music-Enhanced Reciprocal Imitation Training for Autism in Toddlers

      Nashville, Tennessee
      The primary goal of this study is to examine rhythm sensitivity as a predictor of response to naturalistic developmental behavioral intervention (NDBIs) in autistic toddlers. Toddlers receive either Reciprocal Imitation Training (RIT), an evidence-based NDBI that supports children's imitation and social communication skills, or a music-enhanced version of RIT. Throughout their participation in the intervention, toddlers will complete study procedures of viewing naturalistic videos of infant-directed singing and other social scenes while eye gaze data is collected.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:18 - 36

      Key Eligibility Criteria

      Disqualifiers:Hearing Impairment, Seizure Disorder, Others

      40 Participants Needed

      Vocal Optimization for Autism Spectrum Disorder

      Nashville, Tennessee
      Thirty percent of children with autism barely talk or do not talk at all despite years of intervention. This study aims to address this important and long-standing challenge by developing a novel intervention to increase the quantity and quality of vocalizations (i.e., sounds children make before words) and expressive language in young children with autism (aged 2 to 5 years) with minimal verbal skills. The intervention includes contingent responses to the child's vocalizations and vocal elicitation strategies. We also collect social validity information from parents about how they perceive the novel intervention.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:2 - 5

      Key Eligibility Criteria

      Disqualifiers:Uncorrected Visual, Hearing, Severe Motor, Others

      20 Participants Needed

      SENSE Theatre for Autism

      Nashville, Tennessee
      This trial tests SENSE Theatre®, a program that uses acting to help adults with autism improve their social skills. It focuses on practicing face recognition and social interactions through repeated role-playing activities. The goal is to see if these improvements last. SENSE Theatre® is a novel intervention that combines trained peers to facilitate performance-based theatrical treatment in a supportive, community-based environment.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Age:18 - 35

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      72 Participants Needed

      Risperidone vs Aripiprazole for Weight Gain in Children with Autism

      Nashville, Tennessee
      This trial is comparing two medicines, aripiprazole and risperidone, to see which one causes more weight gain in children with autism. The study focuses on children under 18 who have behavior problems like irritability and aggression. These medicines help by calming brain activity to improve behavior. The main goal is to find out which medicine leads to less weight gain over a few months. Aripiprazole and risperidone are both FDA-approved for treating irritability in children with autism.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 4
      Age:< 17

      Key Eligibility Criteria

      Disqualifiers:Age 18+, No Autism Diagnosis
      Must Not Be Taking:Atypical Antipsychotics

      350 Participants Needed

      12345

      Know someone looking for new options?
      Spread the word

      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
      Match to a Trial
      Match to a Trial

      Frequently Asked Questions

      How much do Autism clinical trials pay?

      Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

      How do Autism clinical trials work?

      After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Autism trials 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length for Autism is 12 months.

      How do I participate in a study as a "healthy volunteer"?

      Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

      What does the "phase" of a clinical trial mean?

      The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

      Do I need to be insured to participate in a Autism medical study?

      Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

      What are the newest Autism clinical trials?

      Most recently, we added Caregiver Interventions for Autism, Community Engagement for Autism and SDARI Program for Autism to the Power online platform.

      Is there still a spectrum for autism?

      Yes—medical guidelines still call it Autism Spectrum Disorder, but experts no longer picture that spectrum as a single line from “mild” to “severe.” Instead, it’s more like a sound-mixing board with many sliders: social communication, repetitive behaviors, sensory sensitivity, thinking style, and support needs can each sit at different points, creating a unique profile for every autistic person. Clinicians note these differences by assigning support levels (1-3) in each domain so interventions can be tailored rather than ranked.

      What is the biggest symptom of autism?

      There isn’t one “biggest” symptom of autism; doctors look for a pattern that includes BOTH social-communication differences (like trouble reading body language or carrying on back-and-forth conversation) and restricted, repetitive behaviours or intense interests/sensory sensitivities (such as needing strict routines or reacting strongly to noises). Which of these stands out most varies from person to person, so if you notice a persistent mix of them, the next step is to talk with your GP or a psychologist for a formal autism assessment and tailored support.

      Can maternal stress cause autism?

      Normal day-to-day worries during pregnancy have not been proven to cause autism. Large studies show that only very severe or long-lasting stress (such as the death of a close relative or a natural disaster) is linked to a small rise in risk—about 2 % to roughly 3 %—and even that link may partly reflect other genetic or environmental factors. Taking steps to manage high stress is good for overall maternal and baby health, but parents should not blame themselves or everyday stressors if a child is later diagnosed with autism.

      What is the life expectancy of someone with autism?

      Large registry studies (e.g., Sweden 2016, Denmark 2022) find that autistic people, on average, die 15–20 years earlier than non-autistic peers, with a median age of death around the mid-50s; the figure is lower (≈ 40s) when someone also has intellectual disability or uncontrolled epilepsy and higher (late 50s or beyond) when those conditions are absent. The gap is driven less by autism itself than by treatable or preventable issues—seizures, heart disease, accidents and suicide—so good medical follow-up, mental-health support and safety planning can help many autistic individuals live into typical older age.

      What is the best treatment for autism in the world?

      There is no one “best” treatment for every person with autism; the strongest evidence shows that progress comes from an individualized program that blends proven developmental-behavioral therapies (such as Applied Behavior Analysis or other naturalistic approaches) with speech-language and occupational therapy, parent coaching, and tailored educational supports. A multidisciplinary team adjusts this mix over time—and may add medication for anxiety, ADHD, or sleep problems—so the plan fits the person’s specific strengths, challenges, and goals, which is what international guidelines recommend for the best results.

      Is autism overdiagnosed?

      Rates of autism have risen sharply (e.g., from about 1 in 150 U.S. children in 2000 to 1 in 36 today), but most of that jump comes from broader definitions, better screening, and shifting other labels to “autism,” not from a sudden epidemic. Studies suggest roughly 1 in 10 people once given the label later lose it—evidence of some over-diagnosis—yet girls, adults, and many minority children are still frequently missed, so the real problem is uneven diagnosis rather than simply “too much” or “too little.” A careful, multidisciplinary assessment that also checks for ADHD, language disorders, anxiety, and other look-alike conditions is the best way to get an accurate answer for any individual.

      Who carries the autism gene?

      There is no single “autism gene.” Autism risk comes from a mix of many common genetic variants, rare mutations, and sometimes new (de-novo) changes that neither parent had; these can be inherited from either mother or father, while factors like higher paternal age and the female-protective effect can influence how that risk shows up. In short, either parent—or neither, if the change is new—can pass along genetic risk, so talking with a genetic counselor is the best way to understand a specific family’s situation.

      Which state has the highest rate of autism?

      In the latest CDC ADDM study, the surveillance area in California recorded the highest autism rate: roughly 4.5 % of 8-year-olds (about 45 children per 1,000). However, ADDM covers only parts of 11 states and other tracking systems use different methods, so rankings can change if you look at school records, insurance data, or adult estimates—meaning the numbers are useful for spotting trends, not declaring a single “most-autistic” state.

      Has anyone ever overcome autism?

      Autism is a lifelong neuro-developmental difference, so people don’t “overcome” it in the sense of being cured; instead, most continue to be autistic throughout life. With early, individualized supports and ongoing accommodations, many children and adults make major gains—some even lose the formal diagnosis—yet they often keep certain autistic traits and still benefit from understanding and acceptance. The practical aim is therefore not to erase autism but to build skills, reduce distress, and create environments where each autistic person can thrive.

      What was autism called in the 1980s?

      In the early-1980s diagnostic manual (DSM-III, 1980) autism was officially listed as “Infantile Autism,” and in the 1987 revision (DSM-III-R) the name was changed to “Autistic Disorder” under the larger category of “Pervasive Developmental Disorders.” Outside the U.S., doctors using the World Health Organization’s ICD-9 still called it “Childhood Autism.” In everyday practice, people might also have heard “Kanner’s autism” or “childhood psychosis,” but the two formal labels you would have seen on a medical chart during that decade were “Infantile Autism” at the start of the 1980s and “Autistic Disorder” by the end.